Navigation Links
Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market
Date:7/31/2014

New York, New York (PRWEB) July 31, 2014

The controversy surrounding uterine morcellation continues to grow, as Bernstein Liebhard LLP notes that Johnson & Johnson’s Ethicon, Inc. unit has announced that it plans to voluntarily remove its power morcellators (http://www.gynecaremorcellatorlawsuit.com/) from the market. According to a report from Bloomberg.com, the company said it decided to do so because the risks and benefits associated with the devices remain uncertain.*

“In light of mounting evidence linking uterine morcellation to the spread of undetected cancers, it’s not surprising that Johnson & Johnson’s Ethicon unit has decided to pull its power morcellators from the market,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating morcellator lawsuits on behalf of women who may have experienced the spread of undiagnosed cancers due to uterine morcellation.

Morcellation and Uterine Cancer
Power morcellators are used to cut up tissue during laparoscopic hysterectomy and fibroid removal so that it can be removed through a small abdominal incision. According to Bloomberg.com, Johnson & Johnson and Ethicon decided to suspend sales of the power morcellators on April 30, 2014, after the U.S. Food & Drug Administration (FDA) warned that use of the devices in gynecological procedures could spread undetected uterine cancer cells throughout a woman’s body, resulting in an upstaging of the disease and greatly reducing her chances of long-term survival.

Since the FDA issued its alert, the controversy surrounding uterine morcellation has only grown. Earlier this month, the agency convened a panel of outside advisors to discuss the matter. According to a report from The Boston Globe, the panelists heard emotional testimony from cancer victims and their families, many of whom urged the FDA to ban power morcellators.**

On July 22nd, the Journal of the American Medical Association published a study that suggested the concerns surrounding uterine morcellation are well-founded. Among other things, the study found that as many as 1 in 368 women undergoing such procedures may have undiagnosed cancers present in their uterus. While women over 65 were more likely to have undetected cancer, the study found that 32 percent of the morcellation patients with undiagnosed disease were younger than 50.**

Women who allegedly experienced the spread of uterine cancers due to a power morcellator may be entitled to compensation from the manufacturer of the device used in their surgery. To learn more about the process for filing a morcellator lawsuit, please visit Bernstein Liebhard LLP’s website. To obtain a free legal review, please call 800-511-5092.

*bloomberg.com/news/2014-07-31/j-j-withdraws-hysterectomy-device-tied-to-cancer-spread.html, Bloomberg.com, July 31, 2014
**bostonglobe.com/lifestyle/health-wellness/2014/07/11/agreement-reached-whether-fda-should-ban-hysterectomy-cutting-tool/EkXZaFAUUnT5HZ7DBQvWbM/story.html, Boston Globe, July 11, 2014
***jama.jamanetwork.com/article.aspx?articleid=1890400, JAMA, July 22, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.gynecaremorcellatorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/morcellator-lawsuit/morcellator-cancer/prweb12062778.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk
2. Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation
3. Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System
4. World’s Largest Uterine Fibroid Removed from Patient
5. Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk
6. Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer
7. Study examines presence of uterine cancers at the time of hysterectomy using morcellation
8. FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids
9. Journal Maturitas publishes position statement on management of uterine fibroids
10. Bariatric surgery decreases risk of uterine cancer
11. DrugRisk Alerts of New Rise In Mirena Lawsuits Alleging Uterine Damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion ... and safety labels , has been featured in the National Electrical Manufacturers ... eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication ...
(Date:5/24/2016)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. Drs. ... a complete dental treatment plan that is unique to each smile. , Dr. Kayne ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... ... May 24, 2016 , ... Today ... module. The cutting-edge feature provides end users with an embedded, real time ... intelligence solution and its analytics engine. , This powerful addition to ...
(Date:5/24/2016)... TN (PRWEB) , ... May 24, 2016 , ... ... vitamin alkaline water, a revolutionary new beverage for pregnant women to prevent morning ... prenatal vitamins and alkaline minerals with the look and taste of water. , ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... COUNTY, Calif. , May 19, 2016 /PRNewswire/ ... two thirds of the world lacks basic diagnostic ... procedures in the United States ... privileged to such technology. In fact, the WHO ... at risk of avoidable or treatable death, simply ...
(Date:5/19/2016)... -- According to a new market research report "Sunitinib ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected ... 13.9% from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... spread through 26 Pages and in-depth TOC on "Sunitinib ...
(Date:5/19/2016)... , The data will be presented in ... The conclusions of the study point to a ... 90% of the m presenting duration ... of the patients had clinical benefit.     ... study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed ...
Breaking Medicine Technology: